Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has appointed Moncef Slaoui, PhD, to its ...

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...

Meta boss Mark Zuckerberg has accused the Joe Biden administration of “pushing” to censor posts about the Covid-19 vaccine on ...

British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Scientists from Duke-NUS Medical School and the Singapore General Hospital have discovered that T cells—white blood cells ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Germany's biologics market, the largest in Europe, is expected to grow at a 3.8% CAGR from 2025 to 2035. AI is driving this growth by enhancing R&D, optimizing drug design, and identifying novel ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...